Advance on mechanism of type 2 diabetes mellitus increasing the risk of Parkinson's disease

doi:10.3969/j.issn.1672-6731.2023.06.016

Abstract

Abstract:

Parkinson's disease(PD), in which neurotoxicity caused by hyperglycemia and cerebral insulin resistance may play important roles, and the specific mechanism is not certain.Chronic hyperglycemia may lead to the injury of substantia nigra dopaminergic neuron by promoting oxidative stress, neuroinflammation, the formation of advanced glycation end products and endogenous neurotoxin.Moreover, insulin resistance may be involved in several pathways.This article mainly reviews the mechanism of T2DM increasing the risk of PD and provides guidance for the prevention and treatment of PD in patients with T2DM.

Key words: Parkinson's disease, Diabetes mellitus, type 2, Hyperglycemia, Insulin resistance, Review

摘要：

2型糖尿病与帕金森病的发生发展密切相关，其中高血糖导致的神经毒性和脑组织胰岛素抵抗发挥重要作用，但具体机制尚不明确。慢性血糖升高可能通过促进氧化应激、神经炎症、晚期糖基化终末产物和内源性神经毒素形成，导致黑质多巴胺能神经元损伤，而胰岛素抵抗通过多种途径参与其中。本文对2型糖尿病增加帕金森病风险的作用机制进行综述，为2型糖尿病患者的帕金森病预防与治疗提供指导。

关键词: 帕金森病, 糖尿病, 2型, 高血糖症, 胰岛素抵抗, 综述

Min WANG, Jie QIN, Lan-xin LI, Xin LI, Lei CHEN. Advance on mechanism of type 2 diabetes mellitus increasing the risk of Parkinson's disease[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2023, 23(6): 566-570.

王敏, 秦洁, 李岚昕, 李欣, 陈蕾. 2型糖尿病增加帕金森病风险相关机制研究进展[J]. 中国现代神经疾病杂志, 2023, 23(6): 566-570.

/ / Recommend / Download Citations

URL: https://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2023.06.016

https://journal11.magtechjournal.com/cjcnn/EN/Y2023/V23/I6/566

References 45

1	Bloem BR , Okun MS , Klein C . Parkinson's disease. Lancet, 2021, 397: 2284- 2303. doi: 10.1016/S0140-6736(21)00218-X
2	Parkinson's Disease and Movement Disorders Group, Neurology Branch, Chinese Medical Association , Parkinson's Disease and Movement Disorders Group, Neurologist Branch, Chinese Medical Doctor Association . Chinese guidelines for the treatment of Parkinson's disease(fourth edition). Zhonghua Shen Jing Ke Za Zhi, 2020, 53: 973- 986. doi: 10.3760/cma.j.cn113694-20200331-00233
	中华医学会神经病学分会帕金森病及运动障碍学组, 中国医师协会神经内科医师分会帕金森病及运动障碍学组. 中国帕金森病治疗指南(第四版). 中华神经科杂志, 2020, 53: 973- 986. doi: 10.3760/cma.j.cn113694-20200331-00233
3	Cheong JLY , de Pablo'Fernandez E , Foltynie T , Noyce AJ . The association between type 2 diabetes mellitus and Parkinson's disease. J Parkinsons Dis, 2020, 10: 775- 789. doi: 10.3233/JPD-191900
4	Fralick M , Jenkins AJ , Khunti K , Mbanya JC , Mohan V , Schmidt MI . Global accessibility of therapeutics for diabetes mellitus. Nat Rev Endocrinol, 2022, 18: 199- 204. doi: 10.1038/s41574-021-00621-y
5	Sanz FJ , Solana-Manrique C , Lilao-Garzón J , Brito-Casillas Y , Muñoz-Descalzo S , Paricio N . Exploring the link between Parkinson's disease and type 2 diabetes mellitus in Drosophila. FASEB J, 2022, 36: e22432.
6	Bayram E , Litvan I . Lowering the risk of Parkinson's disease with GLP-1 agonists and DPP4 inhibitors in type 2 diabetes. Brain, 2020, 143: 2868- 2871. doi: 10.1093/brain/awaa287
7	Driver JA , Smith A , Buring JE , Gaziano JM , Kurth T , Logroscino G . Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. Diabetes Care, 2008, 31: 2003- 2005. doi: 10.2337/dc08-0688
8	Chohan H , Senkevich K , Patel RK , Bestwick JP , Jacobs BM , Ciga SB , Gan-Or Z , Noyce AJ . Type 2 diabetes as a determinant of Parkinson's disease risk and progression. Mov Disord, 2021, 36: 1420- 1429. doi: 10.1002/mds.28551
9	Ou R , Wei Q , Hou Y , Zhang L , Liu K , Lin J , Jiang Z , Song W , Cao B , Shang H . Effect of diabetes control status on the progression of Parkinson's disease: a prospective study. Ann Clin Transl Neurol, 2021, 8: 887- 897. doi: 10.1002/acn3.51343
10	De Pablo-Fernandez E , Sierra-Hidalgo F , Benito-León J , Bermejo-Pareja F . Association between Parkinson's disease and diabetes: data from NEDICES study. Acta Neurol Scand, 2017, 136: 732- 736. doi: 10.1111/ane.12793
11	Lu L , Fu DL , Li HQ , Liu AJ , Li JH , Zheng GQ . Diabetes and risk of Parkinson's disease: an updated meta-analysis of case-control studies. PLoS One, 2014, 9: e85781. doi: 10.1371/journal.pone.0085781
12	Lv YQ , Yuan L , Sun Y , Dou HW , Su JH , Hou ZP , Li JY , Li W . Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson's disease mouse mode. Transl Neurodegener, 2022, 11: 14. doi: 10.1186/s40035-022-00288-z
13	Sharma S , Taliyan R . High fat diet feeding induced insulin resistance exacerbates 6-OHDA mediated neurotoxicity and behavioral abnormalities in rats. Behav Brain Res, 2018, 351: 17- 23. doi: 10.1016/j.bbr.2018.05.025
14	Athauda D , Maclagan K , Skene SS , Bajwa-Joseph M , Letchford D , Chowdhury K , Hibbert S , Budnik N , Zampedri L , Dickson J , Li Y , Aviles-Olmos I , Warner TT , Limousin P , Lees AJ , Greig NH , Tebbs S , Foltynie T . Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet, 2017, 390: 1664- 1675. doi: 10.1016/S0140-6736(17)31585-4
15	Hong JM , Choi ES , Park SY . Selective brain cooling: a new horizon of neuroprotection. Front Neurol, 2022, 13: 873165. doi: 10.3389/fneur.2022.873165
16	Grieco M , Giorgi A , Gentile MC , d'Erme M , Morano S , Maras B , Filardi T . Glucagon-like peptide-1: a focus on neurodegenerative diseases. Front Neurosci, 2019, 13: 1112. doi: 10.3389/fnins.2019.01112
17	Bayarsaikhan E , Bayarsaikhan D , Lee J , Son M , Oh S , Moon J , Park HJ , Roshini A , Kim SU , Song BJ , Jo SM , Byun K , Lee B . Microglial AGE-albumin is critical for neuronal death in Parkinson's disease: a possible implication for theranostics. Int J Nanomedicine, 2016, 10: 281- 292. doi: 10.2147/IJN.S95077
18	Song DW , Xin N , Xie BJ , Li YJ , Meng LY , Li HM , Schläppi M , Deng YL . Formation of a salsolinol-like compound, the neurotoxin, 1-acetyl-6, 7-dihydroxy-1, 2, 3, 4-tetrahydroisoquinoline, in a cellular model of hyperglycemia and a rat model of diabetes. Int J Mol Med, 2014, 33: 736- 742. doi: 10.3892/ijmm.2013.1604
19	Sergi D , Renaud J , Simola N , Martinoli MG . Diabetes, a contemporary risk for Parkinson's disease: epidemiological and cellular evidences. Front Aging Neurosci, 2019, 11: 302. doi: 10.3389/fnagi.2019.00302
20	Papachristoforou E , Lambadiari V , Maratou E , Makrilakis K . Association of glycemic indices(hyperglycemia, glucose variability, and hypoglycemia)with oxidative stress and diabetic complications. J Diabetes Res, 2020, 7489795.
21	Su CJ , Shen Z , Cui RX , Huang Y , Xu DL , Zhao FL , Pan J , Shi AM , Liu T , Yu YL . Thioredoxin-Interacting Protein(TXNIP)regulates Parkin/PINK1-mediated mitophagy in dopaminergic neurons under high-glucose conditions: implications for molecular links between Parkinson's disease and diabetes. Neurosci Bull, 2020, 36: 346- 358. doi: 10.1007/s12264-019-00459-5
22	Pérez-Taboada I , Alberquilla S , Martín ED , Anand R , Vietti-Michelina S , Tebeka NN , Cantley J , Cragg SJ , Moratalla R , Vallejo M . Diabetes causes dysfunctional dopamine neurotransmission favoring nigrostriatal degeneration in mice. Mov Disord, 2020, 35: 1636- 1648. doi: 10.1002/mds.28124
23	Renaud J , Bassareo V , Beaulieu J , Pinna A , Schlich M , Lavoie C , Murtas D , Simola N , Martinoli MG . Dopaminergic neurodegeneration in a rat model of long-term hyperglycemia: preferential degeneration of the nigrostriatal motor pathway. Neurobiol Aging, 2018, 69: 117- 128. doi: 10.1016/j.neurobiolaging.2018.05.010
24	Kouli A , Camacho M , Allinson K , Williams-Gray CH . Neuroinflammation and protein pathology in Parkinson's disease dementia. Acta Neuropathol Commun, 2020, 8: 211. doi: 10.1186/s40478-020-01083-5
25	Ho MS . Microglia in Parkinson's disease. Adv Exp Med Biol, 2019, 1175: 335- 353.
26	Li Y , Long W , Gao M , Jiao F , Chen Z , Liu M , Yu L . TREM2 regulates high glucose-induced microglial inflammation via the NLRP3 signaling pathway. Brain Sci, 2021, 11: 896. doi: 10.3390/brainsci11070896
27	Gritsenko A , Green JP , Brough D , Lopez-Castejon G . Mechanisms of NLRP3 priming in inflammaging and age related diseases. Cytokine Growth Factor Rev, 2020, 55: 15- 25. doi: 10.1016/j.cytogfr.2020.08.003
28	Gordon R , Albornoz EA , Christie DC , Langley MR , Kumar V , Mantovani S , Robertson AAB , Butler MS , Rowe DB , O'Neill LA , Kanthasamy AG , Schroder K , Cooper MA , Woodruff TM . Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med, 2018, 10: eaah4066. doi: 10.1126/scitranslmed.aah4066
29	Söderbom G , Zeng BY . The NLRP3 inflammasome as a bridge between neuro-inflammation in metabolic and neurodegenerative diseases. Int Rev Neurobiol, 2020, 154: 345- 391.
30	Kuzan A . Toxicity of advanced glycation end products(Review). Biomed Rep, 2021, 14: 46. doi: 10.3892/br.2021.1422
31	Khalid M , Petroianu G , Adem A . Advanced glycation end products and diabetes mellitus: mechanisms and perspectives. Biomolecules, 2022, 12: 542. doi: 10.3390/biom12040542
32	Chrysanthou M , Estruch IM , Rietjens IMCM , Wichers HJ , Hoppenbrouwers T . In vitro methodologies to study the role of advanced glycation end products(AGEs)in neurodegeneration. Nutrients, 2022, 14: 363. doi: 10.3390/nu14020363
33	Uceda AB , Frau J , Vilanova B , Adrover M . Glycation of α-synuclein hampers its binding to synaptic-like vesicles and its driving effect on their fusion. Cell Mol Life Sci, 2022, 79: 342. doi: 10.1007/s00018-022-04373-4
34	Miranda HV , El-Agnaf OMA , Outeiro TF . Glycation in Parkinson's disease and Alzheimer's disease. Mov Disord, 2016, 31: 782- 790. doi: 10.1002/mds.26566
35	Long H , Zhang S , Zeng S , Tong Y , Liu J , Liu C , Li D . Interaction of RAGE with α-synuclein fibrils mediates inflammatory response of microglia. Cell Rep, 2022, 40: 111401. doi: 10.1016/j.celrep.2022.111401
36	Deng Y , Zhang Y , Li Y , Xiao S , Song D , Qing H , Li Q , Rajput AH . Occurrence and distribution of salsolinol-like compound, 1-acetyl-6, 7-dihydroxy-1, 2, 3, 4-tetrahydroisoquinoline(ADTIQ)in parkinsonian brains. J Neural Transm(Vienna), 2012, 119: 435- 441. doi: 10.1007/s00702-011-0724-4
37	Cao Y , Li B , Ismail N , Smith K , Li T , Dai R , Deng Y . Neurotoxicity and underlying mechanisms of endogenous neurotoxins. Int J Mol Sci, 2021, 22: 12805. doi: 10.3390/ijms222312805
38	Xie B , Lin F , Ullah K , Peng L , Ding W , Dai R , Qing H , Deng Y . A newly discovered neurotoxin ADTIQ associated with hyperglycemia and Parkinson's disease. Biochem Biophys Res Commun, 2015, 459: 361- 366. doi: 10.1016/j.bbrc.2015.02.069
39	Bonnet R , Pavlovic S , Lehmann J , Rommelspacher H . The strong inhibition of triosephosphate isomerase by the natural beta-carbolines may explain their neurotoxic actions. Neuroscience, 2004, 127: 443- 53. doi: 10.1016/j.neuroscience.2004.05.002
40	Pomytkin I , Pinelis V . Brain insulin resistance: focus on insulin receptor-mitochondria interactions. Life(Basel), 2021, 11: 262.
41	Fiory F , Perruolo G , Cimmino I , Cabaro S , Pignalosa FC , Miele C , Beguinot F , Formisano P , Oriente F . The relevance of insulin action in the dopaminergic system. Front Neurosci, 2019, 13: 868. doi: 10.3389/fnins.2019.00868
42	Iravanpour F , Dargahi L , Rezaei M , Haghani M , Heidari R , Valian N , Ahmadiani A . Intranasal insulin improves mitochondrial function and attenuates motor deficits in a rat 6-OHDA model of Parkinson's disease. CNS Neurosci Ther, 2021, 27: 308- 319. doi: 10.1111/cns.13609
43	Sharma SK , Chorell E , Steneberg P , Vernersson-Lindahl E , Edlund H , Wittung-Stafshede P . Insulin-degrading enzyme prevents α-synuclein fibril formation in a nonproteolytical manner. Sci Rep, 2015, 5: 12531. doi: 10.1038/srep12531
44	Hong CT , Chen KY , Wang W , Chiu JY , Wu D , Chao TY , Hu CJ , Chau KYD , Bamodu OA . Insulin resistance promotes Parkinson's disease through aberrant expression of α-synuclein, mitochondrial dysfunction, and deregulation of the polo-like kinase 2 signaling. Cells, 2020, 9: 740. doi: 10.3390/cells9030740
45	Ramasubbu K , Rajeswari VD . Impairment of insulin signaling pathway PI3K/Akt/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases: a perspective review. Mol Cell Biochem, 2023, 478: 1307- 1324. doi: 10.1007/s11010-022-04587-x

[1]	Zhi-yong TONG. Intracranial aneurysms and cerebral revascularization [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(8): 595-598.
[2]	Zhi-yong TONG. History of cerebral revascularization [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(8): 599-605.
[3]	Ling-ji JIN, Jun-wen HU, Yin LI, Lin WANG. Intracranial-intracranial bypass for the treatment of complex intracranial aneurysms: technical advances and surgical experience [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(8): 606-612.
[4]	Pei-xi LIU, Yuan SHI, Wei ZHU. Application of whole-region cerebral vascular bypass for intracranial aneurysms treatment in the flow diversion era [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(8): 613-618.
[5]	Feng ZHANG, Fan-gang MENG. Research progress of subthalamic nucleus deep brain stimulation in treatment of autonomic nerve dysfunction in Parkinson's disease [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(7): 510-515.
[6]	Gui-zhi WU, Hong TIAN. Clinical research progress of deep brain stimulation for Meige's syndrome [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(7): 516-521.
[7]	Fan-gang MENG, Jian-guo ZHANG. Application of retroauricular bone grinding groove technology in deep brain stimulation [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(7): 522-524.
[8]	Lin CHEN, Hua PAN. Electrophysiological diagnosis of functional tremor [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(7): 573-578.
[9]	Jun-ji WEI, Jian-bo CHANG. Promoting the concept of neurosurgical critical care in primary hospitals [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(6): 403-406.
[10]	Ruo-lin SHI, Xiu-jie GAO, Jia-ning CUI, Yan SHAO, Lu-shuang XIE, Yi LIU. Advance on association between 5-hydroxytryptamine and non-motor symptoms in Parkinson's disease [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(6): 497-501.
[11]	Hai-feng LI. Glucocorticoids remain the basis for treatment of myasthenia gravis in the era of targeted therapies [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(5): 295-307.
[12]	Hong-jia XU, Ya-qing SHU, Pin WANG, Fan LI, Shun-liang XU, Wei QIU, Xiao-yu MA. Advances on the diagnosis and treatment of aquaporin 4 antibody positive neuromyelitis optica spectrum disorders [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(5): 308-314.
[13]	Yu HUANG, Jin-chi LIAO, Ya-qing SHU. Progress on sleep disorders in anti-N-methyl-D-aspartate receptor encephalitis [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(5): 315-319.
[14]	Cai-yun LIU, Tao JIN. Immunotherapeutic potential of dendritic cells in multiple sclerosis [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(5): 320-330.
[15]	Jun-cheng WANG, Yue-yang ZHAO, Qiang YANG, Tao KUAI, Ya-wen PAN. Progress on the regulation of malignant biological behavior of glioma by HMGB1 gene [J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(5): 391-397.

Please choose a citation manager

Content to export